Tech Company Financing Transactions

Rhythm Pharmaceuticals Funding Round

Rhythm Pharmaceuticals, based in Boston, received $25 million in investment from MPM Capital, New Enterprise Associates and Third Rock Ventures.

Transaction Overview

Company Name
Rhythm Pharmaceuticals
Announced On
6/4/2012
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series B
Investors

MPM Capital (Vaughn Kailian)

New Enterprise Associates (Ed Mathers)

Third Rock Ventures (Lou Tartaglia)

Proceeds Purpose
Rhythm will use the proceeds to continue advancing its small-peptide therapeutics for metabolic diseases through Phase 2 clinical trials. RM-131 is a ghrelin agonist currently in a Phase 2 clinical trial for the treatment of diabetic gastroparesis. RM-493, an agonist of the melanocortin 4 receptor (MC4R), is currently in Phase 1 clinical trials for the treatment of obesity and diabetes.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
222 Berkeley St. 12th Floor
Boston, MA 02116
USA
Phone
(857) 264-4280
Website
www.rhythmtx.com
Email Address
[email protected]
Overview
Rhythm (NASDAQ: RYTM) is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases.
Profile
Rhythm Pharmaceuticals LinkedIn Company Profile
Social Media
Rhythm Pharmaceuticals Company Twitter Account
Company News
Rhythm Pharmaceuticals News
Facebook
Rhythm Pharmaceuticals on Facebook
YouTube
Rhythm Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
David Meeker
  David Meeker LinkedIn Profile  David Meeker Twitter Account  David Meeker News  David Meeker on Facebook
Chief Financial Officer
Hunter Smith
  Hunter Smith LinkedIn Profile  Hunter Smith Twitter Account  Hunter Smith News  Hunter Smith on Facebook
Chief Medical Officer
Murray Stewart
  Murray Stewart LinkedIn Profile  Murray Stewart Twitter Account  Murray Stewart News  Murray Stewart on Facebook
Executive Vice President
Jennifer Chien
  Jennifer Chien LinkedIn Profile  Jennifer Chien Twitter Account  Jennifer Chien News  Jennifer Chien on Facebook
Executive Vice President
Yann Mazabraud
  Yann Mazabraud LinkedIn Profile  Yann Mazabraud Twitter Account  Yann Mazabraud News  Yann Mazabraud on Facebook
VP - Human Resources
Simon Kelner
  Simon Kelner LinkedIn Profile  Simon Kelner Twitter Account  Simon Kelner News  Simon Kelner on Facebook

 

 

Browse more venture capital transactions:

Prev: 6/4/2012: Popdust venture capital transaction
Next: 6/4/2012: Acylin Therapeutics venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to record every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.